METASTATIC BREAST CANCER

This phase 3 trial aimed to compare two drugs, ribociclib and palbociclib, in people with a specific type of advanced breast cancer (HR+/HER2- with HER2-enriched features). Participants received one of the drugs combined with hormone therapy. The goal was to see which combination…

This early-stage study tested the safety and best dose of combining the drugs RAD001 and docetaxel in 15 people with metastatic breast cancer. The goal was to find a dose that is tolerable while potentially controlling the disease. The study was terminated early, so results are l…

This phase III trial compared two radiation strategies for cancer that had spread to the brain and returned in new spots after initial radiosurgery. One group received focused radiation only to the new tumors, while the other received whole brain radiation that avoided the memory…

This phase 1 study tested the cancer drug pazopanib in 18 frail elderly patients (aged 75+) with metastatic cancers like kidney, lung, or breast cancer. The goal was to find the highest safe dose by starting at 400 mg daily and increasing if tolerated. The study was terminated ea…

This phase 2 trial aimed to see if trastuzumab deruxtecan (Enhertu) could help people with HER2-positive breast cancer that had spread and did not respond to standard first-line therapy. Only 2 participants were enrolled before the study was terminated early, so the results are v…

This phase 2 trial tested the chemotherapy drug ixabepilone in 13 patients with metastatic breast cancer that had stopped responding to standard treatments. The goal was to see if the drug could shrink tumors or slow the disease. The study was terminated early, so the full result…

This early study tested combining high-intensity focused ultrasound (HIFU) with the immunotherapy drug pembrolizumab (Keytruda) in 13 people with metastatic breast cancer. The goal was to see if the ultrasound could help the immune system better recognize and attack tumors. The t…

This early-stage trial tested a new drug called RP-3467, alone or with olaparib, in 26 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The study was terminated, so full results are no…

This study tested a new drug called BDC-1001, given alone or with another drug (pertuzumab), in people with advanced HER2-positive breast cancer that had already been treated with multiple therapies, including trastuzumab deruxtecan. The goal was to see if the drug could shrink t…

This phase 2 trial tested the drug futibatinib (TAS-120), alone or with the hormone therapy fulvestrant, in people with metastatic breast cancer that has specific FGFR gene changes. The study aimed to see if the treatment could shrink tumors or slow cancer growth. However, the tr…

This phase 2 trial tested a drug called tusamitamab ravtansine, alone or with chemotherapy (gemcitabine), in 50 people with advanced breast or pancreatic cancers that have a specific marker (CEACAM5). The goal was to see if the drug could shrink tumors. The study was terminated e…

This study tested a special PET/CT scan using a radioactive tracer called FES to see estrogen receptor activity in women with advanced, hormone-resistant breast cancer. The goal was to see if the scan could predict how well a new hormone therapy would work. Only 6 people were enr…

This study looked at whether giving radiation to the brain could prevent cancer from spreading there in people with HER2-positive breast cancer that had already spread to other organs. Participants were receiving trastuzumab (Herceptin) plus chemotherapy. The study was stopped ea…

This observational study aimed to measure different types of immune cells in women with advanced breast cancer that has spread. Researchers collected blood and leftover tumor samples to see how these cells change over time. The study was terminated early, so only a small number o…